Lantern Pharma Announces Pricing of $60 Million Public Offering
/PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to...
Source: prnewswire.com
Page 22 - Lantern Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Lantern Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Lantern Pharma Today - Breaking & Trending Today
Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to Further Develop LP-184 as Therapy for Glioblastoma
Share this article Share this article DALLAS, Dec. 17, 2020 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, today announced a collaboration and research agreement with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Kennedy Krieger Institute. The collaboration will focus on the further development of Lantern's LP-184 in glioblastoma multiforme (GBM). Based ...
Source: prnewswire.com
Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers
Share this article DALLAS, Dec. 15, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today new scientific data that substantiates blood brain barrier permeability (BBB) for its drug candidate LP-184. LP-184 is being targeted for treating Glioblastoma Multiforme (GBM), an aggressive malignant form of brain cancer that comprises a...
Source: prnewswire.com